The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Relationship between Vancomycin Trough Concentrations and Nephrotoxicity: a Prospective Multicenter Trial
Open accessAbstract
Several single-center studies have suggested that higher doses of vancomycin, aimed at producing trough concentrations of >15 mg/liter, are associated with increased risk of nephrotoxicity. We prospectively assessed the relative incidence of nephrotoxicity in relation to trough concentration in patients with documented methicillin-resistant Staphylococcus aureus (MRSA) infections at seven hospitals throughout South Carolina. Adult patients receiving vancomycin for at least 72 h with at least one vancomycin trough concentration determined under steady-state conditions were prospectively studied. The relationship between vancomycin trough concentrations of >15 mg/ml and the occurrence of nephrotoxicity was assessed using univariate and multivariate analyses, controlling for age, gender, race, dose, length of therapy, use of other nephrotoxins (including contrast media), intensive care unit (ICU) residence, episodes of hypotension, and comorbidities. Nephrotoxicity was defined as an increase in serum creatinine of 0.5 mg/dl or a ≥50% increase from the baseline for two consecutive measurements. MICs of vancomycin for the MRSA isolates were also determined. A total of 288 patients were studied between February 2008 and June 2010, with approximately one-half having initial trough concentrations of ≥15 mg/ml. Nephrotoxicity was observed for 42 patients (29.6%) with trough concentrations >15 mg/ml and for 13 (8.9%) with trough concentrations of ≤15 mg/ml. Multivariate analysis revealed vancomycin trough concentrations of >15 mg/ml and race (black) as risk factors for nephrotoxicity in this population. Vancomycin trough concentrations of >15 mg/ml appear to be associated with a 3-fold increased risk of nephrotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Klevens, R. M. (2007) · JAMA · doi:10.1001/jama.298.15.1763 · Cited by 3,726
Hidron, A. I., Edwards, J. R., Patel, J., Horan, T. C., Sievert, D. M., Pollock, D. A., Fridkin, S. K., & National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591861 · Cited by 3,724
Cosgrove, S. E., Sakoulas, G., Perencevich, E. N., Schwaber, M. J., Karchmer, A. W., & Carmeli, Y. (2003) · Clinical Infectious Diseases · doi:10.1086/345476 · Cited by 1,964
Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795
Engemann, J. J., Carmeli, Y., Cosgrove, S. E., Fowler, V. G., Bronstein, M. Z., Trivette, S. L., Briggs, J. P., Sexton, D. J., & Kaye, K. S. (2003) · Clinical Infectious Diseases · doi:10.1086/367653 · Cited by 934
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860
Sakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836
The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin
Rybak, M. J. (2006) · Clinical Infectious Diseases · doi:10.1086/491712 · Cited by 774
Moise-Broder, P. A., Forrest, A., Birmingham, M. C., & Schentag, J. J. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443130-00005 · Cited by 757
Lodise, T. P., Lomaestro, B., Graves, J., & Drusano, G. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01602-07 · Cited by 574
Craig, W. A. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00065-5 · Cited by 556
Lodise, T. P., Patel, N., Lomaestro, B. M., Rodvold, K. A., & Drusano, G. L. (2009) · Clinical Infectious Diseases · doi:10.1086/600884 · Cited by 554
Lodise, T. P., Graves, J., Evans, A., Graffunder, E., Helmecke, M., Lomaestro, B. M., & Stellrecht, K. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00113-08 · Cited by 553
Kullar, R., Davis, S. L., Levine, D. P., & Rybak, M. J. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir124 · Cited by 463
Health Care–Associated Invasive MRSA Infections, 2005-2008
Kallen, A. J. (2010) · JAMA · doi:10.1001/jama.2010.1115 · Cited by 439 · cited 1×
“Despite a report of a recent decline in invasive MRSA infections (15), this pathogen remains a major cause of serious infection.”
BackgroundSteinkraus, G., White, R., & Friedrich, L. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm258 · Cited by 420
Styers, D., Sheehan, D. J., Hogan, P., & Sahm, D. F. (2006) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-5-2 · Cited by 387
Charles, P. G. P., Ward, P. B., Johnson, P. D. R., Howden, B. P., & Grayson, M. L. (2004) · Clinical Infectious Diseases · doi:10.1086/381093 · Cited by 384
Wang, G., Hindler, J. F., Ward, K. W., & Bruckner, D. A. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.01388-06 · Cited by 358
Jeffres, M. N., Isakow, W., Doherty, J. A., Micek, S. T., & Kollef, M. H. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.06.014 · Cited by 334
Abramson, M. A., & Sexton, D. J. (1999) · Infection Control & Hospital Epidemiology · doi:10.1086/501641 · Cited by 314
Noskin, G. A., Rubin, R. J., Schentag, J. J., Kluytmans, J., Hedblom, E. C., Smulders, M., Lapetina, E., & Gemmen, E. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1756 · Cited by 299
Harbarth, S., Rutschmann, O., Sudre, P., & Pittet, D. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.2.182 · Cited by 267
Vancomycin: We Can't Get There From Here
Patel, N., Pai, M. P., Rodvold, K. A., Lomaestro, B., Drusano, G. L., & Lodise, T. P. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir078 · Cited by 247
Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy
Wong-Beringer, A., Joo, J., Tse, E., & Beringer, P. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.10.013 · Cited by 178
Increasing Vancomycin Serum Trough Concentrations and Incidence of Nephrotoxicity
Pritchard, L., Baker, C., Leggett, J., Sehdev, P., Brown, A., & Bayley, K. B. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.07.025 · Cited by 161
Vancomycin Ototoxicity: a Reevaluation in an Era of Increasing Doses
Forouzesh, A., Moise, P. A., & Sakoulas, G. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01088-08 · Cited by 124
Haque, N. Z., Cahuayme‐Zuniga, L., Peyrani, P., Reyes, K., Lamerato, L. E., Moore, C. L., Patel, S., Allen, M., Peterson, E. L., Wiemken, T. L., et al. (2010) · CHEST Journal · doi:10.1378/chest.09-2453 · Cited by 101
Sader, H. S., Rhomberg, P. R., & Jones, R. N. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00093-09 · Cited by 97
Maclayton, D. O., Suda, K. J., Coval, K. A., York, C. B., & Garey, K. W. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.08.003 · Cited by 96
Fischer, M. J., Brimhall, B. B., Lezotte, D. C., Glazner, J. E., & Parikh, C. R. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.09.006 · Cited by 92
Lodise, T. P., Miller, C. D., Graves, J. P., Evans, A. M., Graffunder, E. M., Helmecke, M. R., & Stellrecht, K. A. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn329 · Cited by 72
Kaye, K. S., Anderson, D. J., Choi, Y., Link, K., Thacker, P. A., & Sexton, D. J. (2008) · Clinical Infectious Diseases · doi:10.1086/587673 · Cited by 70
Rhee, K. Y., Gardiner, D., & Charles, M. (2005) · Clinical Infectious Diseases · doi:10.1086/430175 · Cited by 38
Cited by
van Hal, S. J., Paterson, D. L., & Lodise, T. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01568-12 · Cited by 639
Elyasi, S., Khalili, H., Dashti-Khavidaki, S., & Mohammadpour, A. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1259-9 · Cited by 436
The Nephrotoxicity of Vancomycin
Filippone, E., Kraft, W., & Farber, J. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.726 · Cited by 416
Innovative approaches to optimizing the delivery of vancomycin in individual patients
Pai, M. P., Neely, M., Rodvold, K. A., & Lodise, T. P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.016 · Cited by 292
Optimizing the Clinical Use of Vancomycin
Álvarez, R., López Cortés, L. E., Molina, J., Cisneros, J. M., & Pachón, J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03147-14 · Cited by 258
Metadata
- Authors
- Bosso, J. A., Nappi, J., Rudisill, C., Wellein, M., Bookstaver, P. B., Swindler, J., & Mauldin, P. D.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-12
- Volume
- 55
- Issue
- 12
- Pages
- 5475-5479
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2111442039
- Cited by
- 252
- References
- 35
- FWCI
- 13.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.